New hope for severe obesity? What the proposed £/€250m fund could mean for patients
Italian lawmakers have proposed an amendment to the 2027 budget that would allocate €250 million over three years to subsidise pharmacological treatments for people with severe obesity. If approved, this move would mark a significant policy shift: recognising that drug therapy can be an essential part of long‑term care for a chronic condition that affects millions. But who would qualify, what would be covered, and how might this change the lived experience of patients and families? Let’s unpack the proposal and what it might mean in practical terms.
What exactly does the proposal set out?
The amendment suggests a dedicated fund of €250 million split over three years: €50 million in 2027, and €100 million in each of 2028 and 2029. The money is intended to pilot a reimbursement model for pharmacological therapies aimed at people with severe obesity. In parallel, the amendment proposes a separate €6 million package to introduce screening for adolescents aged 13‑19, coordinated through schools and local health services — a prevention‑focused measure to catch weight issues early.
Who would be eligible for drug reimbursement?
The scheme would not be universal. It targets patients with severe clinical profiles. The criteria proposed are stringent and intended to focus limited resources on those at highest clinical risk:
In other words, the reimbursement would be part of a comprehensive, medically supervised pathway, not a first‑line, standalone option. A therapeutic plan would be defined and overseen by the national medicines agency.
Which medications might be covered?
The amendment does not list specific drugs. Today’s most discussed medicines for weight management include GLP‑1 receptor agonists and other newer agents that have demonstrated meaningful weight loss outcomes in trials. Inclusion in any reimbursement programme would depend on regulatory indications, cost‑effectiveness assessments and AIFA (Italy’s medicines agency) decisions. The pilot model could therefore help determine which agents deliver the best long‑term value for patients and the health system.
Why this matters: equity and chronic disease care
The Italian Society for Obesity (SIO) has welcomed the proposal. The central argument is one of equity: effective treatments exist but remain financially out of reach for many. Obesity is now recognised by Italian law as a chronic, progressive and relapsing disease — a stance that supports long‑term therapeutic approaches rather than one‑off interventions. Subsidising drugs for those with severe disease could reduce disparities in access tied to income or geography.
The adolescent screening element
Alongside treatment funding, the amendment proposes screening programmes for adolescents aged 13‑19, funded with €2 million per year over three years. This aims to identify young people at risk early and provide timely prevention and support, which is crucial — intervening during adolescence can alter lifelong trajectories. Any screening approach will need to account for growth and sex differences in BMI interpretation for under‑18s.
Key benefits and potential risks
Potential benefits:
Potential concerns and challenges:
What would access look like in practice?
According to the proposed framework, access would require a clinical evaluation and a formal therapeutic plan from AIFA. That means patients would typically be assessed in specialised centres, have documentation of prior lifestyle interventions, and meet the comorbidity and BMI thresholds. The pilot nature of the programme suggests that selection and monitoring protocols would be refined over time.
How might this affect patients and families?
For someone with BMI ≥ 40 and related health problems, subsidised medication could be life‑changing: improved mobility, reduced risk of heart disease, better control of obesity‑related conditions and enhanced quality of life. Families often shoulder a heavy emotional and financial burden; public funding for treatment could ease that strain significantly.
Questions still unanswered
What to watch for next
The amendment must pass through parliamentary debate and be finalised in the budget law. If adopted, subsequent work will be needed to define the lists of eligible medicines, the clinical pathway, monitoring indicators and the operational details of adolescent screening. Professional bodies, patient groups and clinicians will all play a role in shaping the final implementation.
